Aetna National Precertification List Updates
September 2019 ~
Aetna has released the latest updates to its National Precertification List (NPL), scheduled to take effect this year through January 2020.
New-To-Market Drugs Requiring Precertification
- Effective Date: March 15, 2019
- UltomirisTM(ravulizumab-cwvz) – precertification for both the drug and the site of care.
- Effective Date: May 15, 2019
- Mavenclad®(cladribine) – This drug is included in the multiple sclerosis drug class.
- Mayzent®(siponimod) – This drug is included in the multiple sclerosis drug class.
- SpravatoTM(esketamine)
- Zolgensma®(onasemnogene abeparvovec-xioi) – precertification for both the drug and the site of care.
- Effective Date: July 1, 2019
- Evenity®(romosozumab-aqqg)
- SkyriziTM(risankizumab-rzaa)
- Herceptin HylectaTM(trastuzumab and hyaluronidase-oysk)
- Effective Date: August 1, 2019
- Cutaquig®(IVIG) – for both the drug and site of care.
- Effective Date: January 1, 2020, for both the drug and the site of care
- Cinryze®(C1 esterase inhibitor)
- Aralast®NP (alpha 1-proteinase inhibitor)
- GlassiaTM(alpha 1-proteinase inhibitor)
- Prolastin®-C (alpha 1-proteinase inhibitor)
- Zemaira®(alpha 1-proteinase inhibitor)
- Aldurazyme®(laronidase)
- Cerezyme®(imiglucerase)
- Elaprase®(idursulfase)
- Elelyso®(taliglucerase alfa)
- Fabrazyme®(agalsidase beta)
- Kanuma®(sebelipase alfa)
- Lumizyme®(alglucosidase alfa)
- MepseviiTM(vestronidase alfa-vjbk)
- Naglazyme®(galsulfase)
- Vimizim®(elosulfase alfa)
- VPRIV®(velaglucerase alfa)
No Longer Requiring Precertification
- Effective Date: January 1, 2020
- Krystexxa®(pegloticase)
- Gazyva®(obinutuzumab)
For more information about Aetna’s precertification changes, refer to the payer’s NPL under the General Information section.
Source(s): Aetna Office Link Updates;
